Erik Amble

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Alertis Medical AS was established in 2000 to develop and commercialize a unique technology for the early detection of critical conditions related to blood supply and respiration, addressing considerable unmet needs in medicine. The patented technology originates from the anesthesiologist Prof T. I. Tønnessen, MD, PhD, and the physicist P. Mirtaheri, PhD, at Rikshospitalet University Hospital, Oslo

Weifa ASA engages in the development, production and sales of medicines and other health products. Its products include medicines for pain relief, cough and cold, nutraceuticals, and dermatology. The company was founded by Olaf Weider in 1940 and is headquartered in Oslo, Norway.

GenoVision AS develops reagents and solutions for certain nucleic acid diagnostic markets. It has developed products and protocols for the direct isolation of DNA and RNA from a variety of sample sources such as dried blood, leucocytes, serum, buccal cells, cultured cells, biopsy samples, paraffin embedded tissue sections, animal tissue and yeast cells. GenoVision was formed in 1998 and is headquartered in Oslo, Norway

Glenwood Management develops, owns, manages, and rents apartments. The private company is based in New York, NY and has subsidiaries in the United States.

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.

Serca Pharmaceuticals AS develops, markets, and sells drug treatment products, medicinal products, and equipment for injuries. The company was founded on October 8, 2018 and is headquartered in Lysaker, Norway.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.